NCT00262418

Brief Summary

Comparison of the efficacy and safety of a single administration of ivermectin to a single administration of permethrin for the treatment of scabies

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2004

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2004

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2005

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 4, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 6, 2005

Completed
Last Updated

December 28, 2007

Status Verified

December 1, 2007

First QC Date

December 4, 2005

Last Update Submit

December 19, 2007

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical healing of the skin injuries

    on day28

Secondary Outcomes (3)

  • Decrease of itching

    on day28

  • Amelioration of the life quality

    on day28

  • Number and gravity of adverse events

Interventions

Eligibility Criteria

Age5 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Scabies tunnels
  • Positive microscopic examination (acarids, faeces or ova)
  • Non-specific injuries with a typical distribution pattern
  • Serious itching which increases during the night
  • Family or contacts with similar complaints

You may not qualify if:

  • Treatment for scabies \< 4 weeks ago
  • Treatment with corticoids \< 1 week ago
  • Pregnancy
  • Breast-feeding
  • HIV
  • Serious immunodepressive patients
  • Sensitivity or allergy to one of the components of the study medication
  • Damage of the central nerve system

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Ghent

Ghent, 9000, Belgium

Location

Related Links

MeSH Terms

Conditions

Scabies

Interventions

Permethrin

Condition Hierarchy (Ancestors)

Mite InfestationsEctoparasitic InfestationsSkin Diseases, ParasiticParasitic DiseasesInfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Phenyl EthersEthersOrganic ChemicalsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPyrethrinsCyclopentane MonoterpenesMonoterpenesTerpenes

Study Officials

  • Jean-Marie Naeyaert, MD, PhD

    University Hospital, Ghent

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 4, 2005

First Posted

December 6, 2005

Study Start

July 1, 2004

Study Completion

May 1, 2005

Last Updated

December 28, 2007

Record last verified: 2007-12

Locations